drugset / Trial / NCT03516604
PF-04995274 and Emotional Processing in Un-medicated Depression
RandomizedParallel-groupQuadruple-blindBasic science
Summary
This study will test whether seven days administration of a serotonin receptor subtype 4 (5HT4) agonist called PF-04995274 has positive effects on cognition, emotional processing and neural activity in unmedicated depressed patients compared to placebo. The study will also include a group of patients randomised to seven days administration of citalopram (20 mg), which is a standard treatment for depression.
Timeline
- Start
- 2018-05-16
- Primary completion
- 2022-07-29
- Completion
- 2022-07-29
Publications
- Gillespie AL, de Cates AN, Scaife J, Blandhol M, Martens MAG, Gibson D, Godlewska BR, Howard W, Cowen PJ, Murphy SE, Harmer CJ. Early effects of a novel 5-HT4R agonist (PF-04995274) and the SSRI citalopram on emotional cognition in unmedicated depression: RESTAND study. Br J Psychiatry. 2026 May 28:1-10. doi: 10.1192/bjp.2026.10664. Online ahead of print.
- Murphy SE, de Cates AN, Gillespie AL, Godlewska BR, Scaife JC, Wright LC, Cowen PJ, Harmer CJ. Translating the promise of 5HT4 receptor agonists for the treatment of depression. Psychol Med. 2021 May;51(7):1111-1120. doi: 10.1017/S0033291720000604. Epub 2020 Apr 3.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Citalopram | Small molecule | 20 mg | Oral |
| Subject | PF-04995274 | Small molecule | 15 mg | Oral |